Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial.
Kosar RahimiHamid AmoozgarSoheila ZareifarMahdi ShahriariOmid Reza ZekavatMehran KarimiGholamreza FathpourFazl SalehNader ShakibazadShayan BordbarMohammadreza BordbarPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
High-dose DFO (50 mg/kg) may serve as a promising cardioprotective agent at least at the molecular level in cancer patients treated with DOX. Further multicenter trials with longer follow-ups are needed to investigate its protective role in delayed DOX-induced cardiac damage. Trial registration IRCT, IRCT2016080615666N5. Registered 6 September 2016, http://www.irct.ir/IRCT2016080615666N5 .
Keyphrases
- high dose
- drug induced
- liver failure
- papillary thyroid
- drug delivery
- oxidative stress
- low dose
- clinical trial
- high glucose
- study protocol
- diabetic rats
- phase iii
- respiratory failure
- phase ii
- double blind
- cancer therapy
- randomized controlled trial
- single molecule
- intensive care unit
- open label
- acute respiratory distress syndrome
- mechanical ventilation